Full Press Release Details
Zymeworks Announces Abstract for Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma at the American Society of Clinical Oncology’s Gastrointestinal Cancers Symposium (ASCO GI).
ZYME
Zymeworks Announces Abstract for Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma at the American Society of Clinical Oncology’s Gastrointestinal Cancers Symposium (ASCO GI)
Key Takeaway: Zymeworks Announces Abstract for Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma at the American Society of Clinical Oncology’s Gastrointestinal Cancers Symposium (ASCO GI)
Price reaction · baseline $10.04 (2023-01-13 close) · hit after-hours · 1 other ZYME headline(s) in the window, move may be shared
day 0 close
-0.4%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+23%
120-day peak, hindsight
Typical move
5.4%
average across 7 past catalysts
Cash runway
~35 mo
Minimal dilution risk
Lead asset
ZW49
Phase 1 · HER2-expressing Cancers